315 related articles for article (PubMed ID: 30706429)
1. Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt.
Namba M; Kawaoka T; Aikata H; Kodama K; Uchikawa S; Ohya K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Imamura M; Baba Y; Awai K; Chayama K
Clin J Gastroenterol; 2019 Aug; 12(4):341-346. PubMed ID: 30706429
[TBL] [Abstract][Full Text] [Related]
2. Factors Raising Serum Ammonia Level During Lenvatinib Treatment of Patients With Hepatocellular Carcinoma.
Narita R; Kotoh K; Yoneda A; Motomura M; Harada M
Anticancer Res; 2020 Sep; 40(9):5271-5276. PubMed ID: 32878816
[TBL] [Abstract][Full Text] [Related]
3. Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma.
Hirooka M; Ochi H; Hiraoka A; Koizumi Y; Matsuura B; Joko K; Michitaka K; Abe M; Hiasa Y
Intern Med; 2019 Mar; 58(6):791-795. PubMed ID: 30333428
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
5. Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study.
Chen B; Zhang L; Cheng J; Wu T; Lei J; Yang X; Zhang R; Safadi R; Li Y; Si T; Lu Y
Drug Des Devel Ther; 2022; 16():4429-4437. PubMed ID: 36597443
[TBL] [Abstract][Full Text] [Related]
6. Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib.
Honda S; Saito Y; Sawada K; Hasebe T; Nakajima S; Okumura T
Intern Med; 2020 Mar; 59(5):657-662. PubMed ID: 31735795
[TBL] [Abstract][Full Text] [Related]
7. Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.
Ikeda M; Okusaka T; Mitsunaga S; Ueno H; Tamai T; Suzuki T; Hayato S; Kadowaki T; Okita K; Kumada H
Clin Cancer Res; 2016 Mar; 22(6):1385-94. PubMed ID: 26500236
[TBL] [Abstract][Full Text] [Related]
8. An inferior mesenteric-caval shunt via the internal iliac vein with portosystemic encephalopathy.
Otake M; Kobayashi Y; Hashimoto D; Igarashi T; Takahashi M; Kumaoka H; Takagi M; Kawamura K; Koide S; Sasada Y; Kageyama F; Kawasaki T; Nakamura H
Intern Med; 2001 Sep; 40(9):887-90. PubMed ID: 11579950
[TBL] [Abstract][Full Text] [Related]
9. Effective balloon-occluded retrograde transvenous obliteration of the superior mesenteric vein-inferior vena cava shunt in a patient with hepatic encephalopathy after living donor liver transplantation.
Baimakhanov Z; Soyama A; Takatsuki M; Inoue Y; Matsushima H; Hidaka M; Kitasato A; Adachi T; Kuroki T; Sakomoto I; Eguchi S
Clin J Gastroenterol; 2014 Aug; 7(4):342-5. PubMed ID: 26185885
[TBL] [Abstract][Full Text] [Related]
10. Conversion Hepatectomy for Huge Hepatocellular Carcinoma With Arterioportal Shunt After Chemoembolization and Lenvatinib Therapy.
Sato N; Beppu T; Kinoshita K; Yuki H; Suyama K; Chiyonaga S; Motohara T; Komohara Y; Hara A; Akahoshi S
Anticancer Res; 2019 Oct; 39(10):5695-5701. PubMed ID: 31570469
[TBL] [Abstract][Full Text] [Related]
11. Partial Splenic Embolization for Lenvatinib Therapy-associated Thrombocytopenia Among Patients With Hepatocellular Carcinoma.
Sato N; Beppu T; Kinoshita K; Yuki H; Suyama K; Yuruki H; Motohara T; Chiyonaga S; Akahoshi S
Anticancer Res; 2019 Dec; 39(12):6895-6901. PubMed ID: 31810959
[TBL] [Abstract][Full Text] [Related]
12. Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting.
Hiraoka A; Kumada T; Kariyama K; Tada T; Tani J; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Yasuda S; Toyoda H; Ohama H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Michitaka K; Hiasa Y; Kudo M;
J Gastroenterol Hepatol; 2021 Jul; 36(7):1812-1819. PubMed ID: 33171524
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib induced hepatic encephalopathy.
Sidhu SS; Agarwal S; Goyal O; Kishore H; Sidhu S
Acta Gastroenterol Belg; 2017; 80(4):537-538. PubMed ID: 29560652
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting.
Obi S; Sato T; Sato S; Kanda M; Tokudome Y; Kojima Y; Suzuki Y; Hosoda K; Kawai T; Kondo Y; Isomura Y; Ohyama H; Nakagomi K; Ashizawa H; Miura Y; Amano H; Mochizuki H; Omata M
Hepatol Int; 2019 Mar; 13(2):199-204. PubMed ID: 30671808
[TBL] [Abstract][Full Text] [Related]
15. Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma.
Takahashi A; Moriguchi M; Seko Y; Ishikawa H; Yo T; Kimura H; Fujii H; Shima T; Mitsumoto Y; Ishiba H; Takashima H; Nagao Y; Jo M; Arai M; Hara T; Okajima A; Muramatsu A; Morita A; Yoshinami N; Nakajima T; Mitsuyoshi H; Umemura A; Nishikawa T; Yamaguchi K; Itoh Y
Anticancer Res; 2019 Sep; 39(9):5149-5156. PubMed ID: 31519627
[TBL] [Abstract][Full Text] [Related]
16. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib.
Ikeda M; Kobayashi M; Tahara M; Kaneko S
Expert Opin Drug Saf; 2018 Nov; 17(11):1095-1105. PubMed ID: 30264594
[TBL] [Abstract][Full Text] [Related]
17. Hybrid Surgery for Portosystemic Encephalopathy in a Patient with Liver Cirrhosis: a case report.
Imaoka Y; Ohira M; Kuroda S; Tahara H; Ide K; Ishiyama K; Kobayashi T; Ishikawa M; Awai K; Ohdan H
Hiroshima J Med Sci; 2017 Mar; 66(1):11-15. PubMed ID: 29986123
[TBL] [Abstract][Full Text] [Related]
18. A spontaneous rupture of lung metastasis from hepatocellular carcinoma after the introduction of lenvatinib.
Higashino M; Sugiura R; Yamamoto Y; Naruse H; Sakamoto N
J Gastrointestin Liver Dis; 2021 Mar; 30(1):169-170. PubMed ID: 33723551
[No Abstract] [Full Text] [Related]
19. Adaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosis.
Mukozu T; Nagai H; Matsui D; Mohri K; Watanabe G; Yoshimine N; Amanuma M; Kobayashi K; Ogino Y; Matsukiyo Y; Matsui T; Daido Y; Wakui N; Shinohara M; Momiyama K; Higai K; Igarashi Y
Cancer Chemother Pharmacol; 2022 Jan; 89(1):11-20. PubMed ID: 34628536
[TBL] [Abstract][Full Text] [Related]
20. Lenvatinib-induced Interstitial Pneumonia in a Patient with Hepatocellular Carcinoma.
Imakura T; Sato S; Tomonari T; Murakami K; Takahashi N; Naito N; Mima M; Kagawa K; Koyama K; Nishimura H; Kawano H; Nokihara H; Azuma M; Takayama T; Nishioka Y
Intern Med; 2022 Apr; 61(8):1211-1217. PubMed ID: 34544944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
